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Abstract
Typhoid fever is caused by Salmonella enterica serovar Typhi, a major public health concern in developing countries. Recently, there has
been an upsurge in the occurrence of bacterial isolates that are resistant to ciproﬂoxacin, and the emergence of broad spectrum b-lac-
tamases in typhoidal salmonellae constitutes a new challenge for the clinician. A total of 337 blood culture isolates of S. Typhi, isolated
from Pondicherry, India, between January 2005 and December 2009, were investigated using phenotypic, molecular and serological
methods. Of the 337 isolates, 74 (22%) were found to be multidrug resistant (MDR) and 264 (78%) nalidixic acid resistant (NAR). Iso-
lates with reduced susceptibility to ciproﬂoxacin possessed single mutations in the gyrA gene. A high rate of resistance (8%) was found
to ciproﬂoxacin. All isolates with a ciproﬂoxacin MIC ‡ 4 mg/L possessed both double mutations in the QRDR of the gyrA gene and a
single mutation in the parC gene. Active efﬂux pump mechanisms were also found to be involved in ciproﬂoxacin resistance. Finally, a
large number of PFGE patterns (non-clonal genotypes) were observed among the S. Typhi isolates. In conclusion, a high rate of cipro-
ﬂoxacin resistance was observed in comparison to other endemic areas in blood culture isolates of S. Typhi from Pondicherry, India,
with steadily increasing NAR but decreasing MDR isolations over the study period. This is most likely to be due to an increased use of
ciproﬂoxacin as a ﬁrst-line drug of choice over more traditional antimicrobial agents for the treatment of typhoid fever.
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Introduction
Typhoid fever, caused by Salmonella enterica serovar Typhi, is
a major health problem in developing countries, particularly
in the Indian subcontinent and in southeast Asia. Typhoid
fever is the most serious form of enteric fever and in the
year 2000 it was estimated that the global number of typhoid
cases exceeded 21 000 000, with more than 200 000 deaths
[1]. Further, if not treated properly, enteric fever carries a
mortality rate of 30%, whilst appropriate antimicrobial
treatment reduces the mortality rate to as low as 0.5% [2].
In cases of enteric fever, it is often necessary to commence
treatment before the results of laboratory sensitivity testing
become available, and the ﬂuoroquinolone ciproﬂoxacin has
become the ﬁrst-line drug for treatment, especially since the
widespread emergence of S. Typhi isolates that are multidrug
resistant (MDR) to the more traditional antimicrobial agents
comprising chloramphenicol, ampicillin and trimethoprim-
sulphamethoxazole (cotrimoxazole) [3]. However, this
switch to ciproﬂoxacin has led to a subsequent increase
in the occurrence of S. Typhi isolates resistant to this anti-
microbial agent, including in India [4,5].
In salmonellae, quinolone resistance is usually associated
with mutations in the quinolone resistance-determining
region (QRDR) of the A subunit target site of DNA gyrase,
though the presence of plasmid-mediated quinolone
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resistance qnr genes and aac(6¢)-Ib-cr has also been described
in quinolone-resistant non-Typhi Salmonella [6]. The exact
mechanism of this DNA gyrase-mediated resistance in S. Ty-
phi is not fully understood, though various studies have
found that single point mutations in this region confer resis-
tance to nalidixic acid and hence reduced susceptibility to
ﬂuoroquinolones [7]. In contrast, high-level ciproﬂoxacin
resistance may be due to either (i) the cumulative impact of
mutations in many genes, (ii) decreased membrane perme-
ability, (iii) active efﬂux pump, and/or (iv) the presence of
plasmid-encoded qnr genes [8].
Worldwide, there are sporadic reports of high-level resis-
tance to beta-lactam antibiotics, including ceftriaxone in
typhoidal salmonellae, due to the presence of CTX-M-15 and
SHV-12 extended spectrum b-lactamases (ESBLs) [9,10]. Fur-
ther, we recently reported an ACC-1 AmpC b-lactamase
producing S. Typhi that had been isolated from the blood of
a girl aged 14 years [11].
Therefore, a study was undertaken to characterize trends
in antimicrobial resistance in clinically relevant S. Typhi iso-
lates originating from Pondicherry, India, to help guide clini-
cians in successful treatment therapies.
Materials and Methods
Bacterial culture and identiﬁcation
Blood cultures from a total of 3744 patients presenting with
fever at the Jawaharlal Institute of Postgraduate Medical Edu-
cation and Research (JIPMER), Pondicherry, and Government
General Hospital, Pondicherry, during the period January
2005 to December 2009 were taken for microbial diagnosis.
The patients ranged in age from 2 to 74 years (median,
43 years). Standard blood culture protocols were followed,
including culture on a biphasic medium consisting of Brain
Heart Infusion (BHI) agar and BHI broth (HiMedia Laborato-
ries Ltd, Mumbai, India). Colonies were identiﬁed as S. Typhi
using standard biochemical methods [12], and conﬁrmed
using Salmonella polyvalent O, O9 and H:d antisera (Murex
Biotech, Dartford, England).
Antimicrobial susceptibility testing
Isolates were tested for susceptibility to antimicrobials using
the Kirby Bauer disk diffusion method. Antibiotic disks con-
tained ampicillin (10 lg), cotrimoxazole (25 lg), chloramphe-
nicol (30 lg), ciproﬂoxacin (5 lg), ceftazidime (30 lg),
ceftriaxone (30 lg) and nalidixic acid (10 lg), and results were
interpreted according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines (2007). Reduced susceptibility to
ciproﬂoxacin was determined as a minimum inhibitory concen-
tration (MIC) of 0.125–1.0 mg/L. The breakpoints for oﬂoxa-
cin and gatiﬂoxacin were £2 mg/L (susceptible) and ‡8 mg/L
(resistant), and for ciproﬂoxacin, £1 mg/L (susceptible) and
‡4 mg/mL (resistant) (CLSI, 2007). Escherichia coli ATCC
25922 was used as a control isolate. Nalidixic acid susceptibil-
ity was used as a screening test for reduced susceptibility to
ciproﬂoxacin [13]. MICs were determined by both agar dilu-
tion and E-test (AB Biodisk, Solna, Sweden) for the antibiotics
ciproﬂoxacin, ampicillin, chloramphenicol and ceftriaxone.
MICs against gatiﬂoxacin and oﬂoxacin were determined by
E-test only.
Efﬂux pumps
Testing for antimicrobial resistance via efﬂux pump activity
was performed using the cyclohexane tolerance test [14],
and via the detection of the MIC in the absence and pres-
ence of the efﬂux pump inhibitor (EPI) PabN (Phe-Arg-b-
naphthylamide) at 20 mg/L [15].
Molecular analysis of quinolone resistance
Molecular analysis of quinolone resistance was performed on
57 (27 ciproﬂoxacin resistant, ﬁve ciproﬂoxacin intermediate
and 25 ciproﬂoxacin susceptible) isolates.
The molecular mechanism of quinolone resistance was
determined by investigating mutations in the QRDRs of
DNA gyrase (gyrA and gyrB) and DNA topoisomerase IV
(parC and parE) genes, according to previously described
protocols [16–18].
The possible presence of the plasmid-mediated quinolone
resistance qnr gene (qnrA, qnrB, and qnrS), and aac(6¢)-Ib-cr
gene was determined using PCR [19,20].
Detection of beta-lactamases
PCR screening and sequencing was performed to identify the
b-lactamase resistance genes blaTEM, blaSHV, blaOXA-1 group
and blaCTX-M [21–23]. Beta-lactamase screening was per-
formed for 61 isolates that were highly resistant to ampicillin
(MIC ‡ 256 mg/L). Isoelectric focusing of b-lactamase
enzymes was performed using standard methods [24].
Isolate genotyping
Genotyping was performed on a representative sample of
20 S. Typhi isolates using pulsed ﬁeld gel electrophoresis
(PFGE). Brieﬂy, isolates were incubated overnight at 37C in
7 mL Mueller Hinton broth. After incubation, 1 mL of bacterial
cells was harvested, pelleted and washed three times using
1 mL EET (Na2EDTA 100 mM, EGTA 10 mM, Tris HCl 1 M)
buffer, before being adjusted to a cell density of 0.5 at 560 nm.
One hundred microlitres of cell suspension and 100 lL of
1.4% PFGE grade agarose in EET buffer were mixed and
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poured into PFGE plug moulds. The plugs were incubated at
4C for 30 min to harden and 1 mL of lysozyme (5 mg/mL)
was added before incubation at 37C for 3–4 h. Lysozyme was
removed from the plugs and 1 mL of deproteinising solution
(per plug 3 mg/mL proteinase K and 1% SDS) was added prior
to overnight incubation at 37C. Next, the plugs were washed
six times every 30 min with T10E1 (10 mM Tris, 1 mM EDTA)
buffer, and then soaked in T10E0.1 (10 mM Tris, 0.1 mM
EDTA) buffer for 30 min. Restriction digestion was performed
using 40 U of XbaI (Fermentas, St. Leon-Rot, Germany) at
37C. PFGE was performed in a 1% agarose gel in a CHEF DR-
II system (BioRad, Hercules, CA, USA) with the following con-
ditions: 0.5· Tris–Borate EDTA buffer, 14C, 6 V/cm for 22 h
(with switch times ranging from 5 to 40 s). Lambda ladder
PFGE marker (BioRad) was used as a molecular weight stan-
dard.
Results
Trends in antimicrobial susceptibility of S. Typhi isolates
A total of 337 S. Typhi isolates from two hospitals recovered
during the period 2005–2009 were included in this study,
representing 100% of the S. Typhi isolates recovered during
this period. Of these isolates, 222 (65.9%) were fully suscep-
tible to ampicillin, chloramphenicol and cotrimoxazole; 74
(22.0%) were MDR; 264 (78.3%) were nalidixic acid resistant
(NAR); and 27 (8.0%) were both MDR and NAR (MDR being
deﬁned as resistance to all ﬁrst-line antimicrobials, i.e.
ampicillin, cotrimoxazole and chloramphenicol). The results
are summarized in Table 1. Twenty-seven isolates (8.0%)
were resistant to ciproﬂoxacin. There was a steady decline
in the number of MDR isolates over the 5-year study period,
as well as a parallel increase in NAR (non-MDR) isolates
(Tables 1 and 2 and Fig. 1).
The susceptibility results for different antibiotics as well as
the MIC50 and MIC90 (MICs at which 50% or 90% of the iso-
lates were inhibited) values obtained for 337 S. Typhi isolates
are shown in Table 3. Of the 27 ciproﬂoxacin-resistant
isolates recovered in this study, a single isolate was found to
possess an MIC of >32 mg/L (E-test), whilst the correspond-
ing agar dilution method and HIMEDIA HiComb MIC test
(HiMedia) revealed an MIC of 64 mg/L. In the same isolate,
the MIC of oﬂoxacin and gatiﬂoxacin (E-test), was >32 and
8 mg/L, respectively. For gatiﬂoxacin, the MIC50 and MIC90
were one to two dilution steps lower than those of cipro-
TABLE 1. Distribution of antimi-
crobial resistance to ampicillin, co-
trimoxazole and chloramphenicol
among S. Typhi isolates
Period
of isolation
No.
(%) susceptiblea
No. (%) with
single resistanceb
No. (%) paired
resistancec
No. (%)
MDRd Total no. (%)
2005 24 (34.3) 9 (12.4) 6 (9) 31 (44.2) 70 (20.8)
2006 40 (52.6) 7 (9.2) 3 (4) 26 (34.2) 76 (22.6)
2007 37 (58.7) 8 (12.7) 1 (1.6) 17 (27) 63 (18.7)
2008 65 (94.2) 2 (2.9) 2 (2.9) 0 69 (20.4)
2009 56 (94.9) 3 (5.1) 0 0 59 (17.5)
Total 222 (65.9) 29 (8.6) 12 (3.5) 74 (22) 337 (100)
aSusceptible to ampicillin, chloramphenicol and cotrimoxazole.
bSingle resistance – resistance to only one antimicrobial (ampicillin or cotrimoxazole).
cPaired resistance – resistance to two antimicrobials (ampicillin and chloramphenicol; ampicillin and cotrimoxazole;
and chloramphenicol and cotrimoxazole).
dMDR – deﬁned as resistance to ampicillin, chloramphenicol and cotrimoxazole.
TABLE 2. Trends in resistance to quinolones among S. Ty-
phi isolates during the study period
Period of isolation No. (%) NAR No. (%) CIPR
2005 51 (72.9) 0
2006 57 (75) 5 (6.6)
2007 48 (76.2) 8 (12.7)
2008 58 (84) 9 (13)
2009 50 (83.3) 5 (8.5)
Total 264 (78.3) 27 (8)
CIPR, ciproﬂoxacin resistant; NAR, nalidixic acid resistant.
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FIG. 1. Proportions that were nalidixic acid resistant (NAR) and
multidrug resistant (MDR) among the isolates of S. Typhi. Numbers
in brackets indicate the total number of blood culture positive S. Ty-
phi isolates cultured in each year at Jawaharlal Institute of Postgradu-
ate Medical Education and Research and the Government General
Hospital, Pondicherry, India.
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ﬂoxacin and oﬂoxacin with respect to all isolates tested. Cip-
roﬂoxacin MICs for susceptible isolates ranged between
0.016 and 1 mg/L. A correlation was observed between
reduced ciproﬂoxacin susceptibility and nalidixic acid resis-
tance (231/234 isolates with ciproﬂoxacin MICs ranging from
0.125 to 2 mg/L were NAR). The exceptions were three iso-
lates with 1 mg/L MIC that were nalidixic acid sensitive
(NAS) and MDR. Seventy-one of the isolates possessing cip-
roﬂoxacin MICs of £0.25 mg/L were all NAS and susceptible
to all other antimicrobial agents tested. All 337 isolates were
found to be susceptible to ceftazidime and ceftriaxone,
though interestingly there was a gradual increase in MIC90
values for both ceftazidime and ceftriaxone during the study
period from 0.064 to 0.25 mg/L.
Efﬂux pumps
Using the cyclohexane tolerance test, only a single S. Typhi
isolate (with a ciproﬂoxacin MIC of 64 mg/L) showed evi-
dence of an efﬂux pump-mediated contribution to resistance.
In the presence of EPI, the MIC to ciproﬂoxacin and nalidixic
acid decreased four-fold in all of the 27 isolates possessing
an MIC of ‡4 mg/L.
Molecular analysis of quinolone resistance
The relationship between ciproﬂoxacin MIC and nucleotide
changes within DNA gyrase and topoisomerase IV subunit
genes of 11 isolates, representing different resistance pro-
ﬁles, is shown in Table 4. Isolates with ciproﬂoxacin MICs of
‡1 to <4 mg/L, exhibited a single point mutation in gyrA and
parC genes. NAR isolates with a comparatively reduced sus-
ceptibility to ciproﬂoxacin (MIC 0.125–0.5 mg/L), possessed
a single gyrA mutation (either at Ser83 or Asp87) only. All
ciproﬂoxacin-resistant isolates (MICs ‡ 4 mg/L) showed
three mutations, two mutations within the QRDR of gyrA, at
positions 83 and 87, and a single mutation in parC, at posi-
tion 80. No mutations were detected in QRDRs of gyrA and
parC genes of nalidixic-acid-susceptible isolates, for which
ciproﬂoxacin MICs were <0.125 mg/L. Sequence mutations
in the QRDRs of gyrB and parE genes were not found in any
of the isolates tested.
In some NAS and NAR isolates, irrespective of their MICs
against ciproﬂoxacin (0.015–£4 mg/L; data not shown), a
mutation was found outside the QRDR of gyrA. This substitu-
tion, found outside the QRDR of GyrA, was Gly133 ﬁ Glu.
All isolates were negative for qnr (qnrA, qnrB, and qnrS)
and aac(6¢)-Ib-cr genes.
Detection of beta-lactamase genes
Twelve (20%) of 61 isolates highly resistant to ampicillin iso-
lates were found to be positive for blaTEM-1, with isoelectric
TABLE 3. Antimicrobial sensitivity
patterns obtained for S. Typhi iso-
lates recovered from blood cul-
tures of patients in Pondicherry,
India, between 2005 and 2009
(n = 337)
Antimicrobial
agents
Sensitive
No. (%)
Intermediate
No. (%)
Resistant
No. (%) Range
MIC (mg/L)
MIC50 MIC90
Ampicillin 243 (72.1) 12 (3.6) 82 (24.3) 1–‡256 1 ‡256
Chloramphenicol 255 (75.7) 6 (1.8) 76 (22.6) 1–‡256 2 ‡256
Cotrimoxazole 234 (69.4) 0 103 (30.6) – ND ND
Nalidixic acid 73 (21.7) 0 264 (78.3) – ND ND
Ciproﬂoxacin 305 (90.5) 5 (1.5) 27 (8.0) 0.016–64 0.5 1
Gatiﬂoxacin 324 (96.1) 6 (1.8) 7 (2.1) 0.016–8 0.125 1
Oﬂoxacin 310 (92.0) 4 (1.2) 23 (6.8) 0.016–32 0.5 4
Ceftazidime 337 (100) 0 0 0.064–2 0.25 0.25
Ceftriaxone 337 (100) 0 0 0.064–2 0.25 0.25
ND, not determined.
Seventy-four (22.0%) isolates were multidrug resistant (MDR), deﬁned as being resistant to ampicillin, chlorampheni-
col and cotrimoxazole.
MIC50 and MIC90 = MIC at which 50% and 90% of the isolates were inhibited, respectively.
TABLE 4. Relationship between ciproﬂoxacin MIC, point
mutations within the QRDRs of DNA gyrase and topoisom-
erase IV subunit genes and testing for the effect of efﬂux
pumps in 11 representative S. Typhi isolates
Isolate
no.
CIP MIC
(mg/L)
Amino acid
change in
GyrAa
Amino acid
change in
ParCb Efc
T20 64 (Ser 83 ﬁ Phe),
(Asp 87 ﬁ Asn)
(Ser 80 ﬁ Ile) +
T85 1 (Ser 83 ﬁ Phe) (Thr 57 ﬁ Ser) )
T86 2 (Ser 83 ﬁ Phe) (Ser 80 ﬁ Ile) )
T9 4 (Ser 83 ﬁ Leu),
(Asp 87 ﬁ Asn)
(Ser 80 ﬁ Ile) +
T1 2 (83 Ser ﬁ Tyr) (Thr 57 ﬁ Ser) )
T2 2 (Ser 83 ﬁ Phe) (Ser 80 ﬁ Ile) )
T7 6 (Ser 83 ﬁ Phe),
(Asp 87 ﬁ Asn)
(Ser 80 ﬁ Ile) +
T13 0.015 None None )
T14 0.5 (Ser 83 ﬁ Phe) None )
T18 1 (Ser 83 ﬁ Phe) (Thr 57 ﬁ Ser) )
T21 0.25 (Ser 83 ﬁ Tyr) None )
CIP, ciproﬂoxacin; MIC, minimum inhibitory concentration.
aNucleotide changes in gyrA, 83-TCC (Ser) ﬁ TTC (Phe); 83-TCC (Ser) ﬁ
TAC (Tyr); 83-TCC (Ser) ﬁ TTG (Leu); 87-GAC (Asp) ﬁ AAC (Asn).
bNucleotide changes in parC, 80- AGC (Ser) ﬁ ATC (Ile); 57- ACC (Thr) ﬁ
AGC (Ser). Alterations in the QRDRs of gyrB and parE genes were not found in
any of the strains tested.
cEf – phenotypic test for elucidation of efﬂux mechanism.
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focusing experiments showing a b-lactamase with a pI of 5.4
(TEM-1). Four (7%) of the 61 isolates were positive for
blaOXA-1-like genes, but none of the isolates were positive
for both blaTEM-1 and blaOXA-1. Of the 12 blaTEM-1-positive
isolates, ﬁve were also found to be ciproﬂoxacin resistant.
Genotyping
Twenty isolates were selected for PFGE genotyping, being
representative of the different antibiotic susceptibility proﬁles
obtained from the culture isolates. Overall, 13 different
(non-clonal) PFGE patterns were observed at 95% (Fig. 2).
Discussion
Typhoid fever remains a public health problem in developing
countries such as India. In this study, we investigated 337
blood culture-positive S. Typhi isolates, and similar to previ-
ous research [25] a higher number of culture-positive cases
occurred in persons aged 6–20 years. A gradual decline in
the number of S. Typhi MDR isolates was also observed,
corresponding to the decrease in occurrence of MDR S. Ty-
phi observed in south India, in a previous publication [4].
This was accompanied by an increase in non-MDR isolates,
though the majority of these (78%) were resistant to NAR
and showed reduced susceptibility to ciproﬂoxacin. Further,
antimicrobial resistance was not associated with a particular
clonal genotype of S. Typhi. This ﬁnding is most likely to be
due to decreased prescribing of traditional antimicrobial
agents, and an increasing reliance on ciproﬂoxacin as the
ﬁrst-line treatment for S. Typhi in Pondicherry [5].
Indeed, 8% of S. Typhi isolates from blood cultures in
Pondicherry were found to be highly resistant to ciproﬂoxa-
cin (MIC ‡ 4 mg/L), and the emergence of such resistant
bacteria is a cause of concern. In recent years, there have
been some sporadic reports of high-level ciproﬂoxacin resis-
tance in Salmonella enterica [5]. Raveendran et al. [26] in
2008 reported a ciproﬂoxacin resistance rate of 5.6% in
S. Typhi isolates of New Delhi. However, isolates with
reduced susceptibility to ciproﬂoxacin (‡0.125; NAR isolates)
have a less favourable response to ciproﬂoxacin [3].
In our study, in gyrA, double point mutations were found
in isolates with ciproﬂoxacin MICs ‡ 4 mg/L, with single
mutations in isolates with lower MICs (0.25–2.0 mg/L), with
evidence for the contribution of efﬂux pumps in all isolates
with an MIC ‡ 4 mg/L, similar to an earlier report [27]. All
the isolates with MIC ‡ 1 mg/L, irrespective of their higher
MICs against ciproﬂoxacin, had a single mutation in the parC
gene. Resistance mutations of gyrA have been clustered in a
region of the gene product between amino acids 67 and 106,
termed the QRDR. The substitution Gly133 ﬁ Glu, found in
our study, has been seen in very few sequences in GyrA
from S. Typhi that cover position 133 (GenBank accession
no. AY302588, AY302585, EF176634 and GU190905).
Although this mutation was found in the gene outside of the
QRDR, it was not seen in isolates with MIC > 4 mg/L against
ciproﬂoxacin and hence it is probably not associated with
quinolone resistance in these isolates.
FIG. 2. Pulsed ﬁeld gel electrophoresis
ﬁngerprinting of 20 S. Typhi isolates that
exhibited a range of antimicrobial sus-
ceptibility proﬁles identiﬁed in this
study. Cluster analysis was performed
using the method of dice coefﬁcient
with unweighted pair group method
with arithmetic mean with band toler-
ance set to 2.0%. All isolates were cul-
tured from blood. Antimicrobial drugs:
ciproﬂoxacin (CIP), ampicillin (AMP),
chloramphenicol (CHL), trimethoprim/
sulphamethoxazole (SXT), nalidixic acid
(NAL), ceftriaxone (CRO).
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Several studies have also reported that the ﬁrst and
essential step towards the development of a (quinolone)
resistance phenotype in Salmonella spp. is the acquisition of
mutations that give rise to an increase in efﬂux, with muta-
tions in the QRDR regions only representing a second step
in enhancement of resistance [28]. Bacterial efﬂux pumps
are important mechanisms involved in resistance to many
classes of antimicrobial agents, including ﬂuoroquinolones
[29].
With respect to ampicillin resistance, this was attributable
to the production of TEM-1 or OXA-1 b-lactamases, similar
to the ﬁndings of Ling et al. [30].
There was a gradual increase in MICs against ceftazidime
and ceftriaxone (a third-generation cephalosporin) during
the study period, from a MIC90 value of 0.064 mg/L in
2005 to 0.25 mg/L in 2009, though still well within the sus-
ceptible range. This type of resistance to quinolones, and
more recently, increases in MIC levels to third- and fourth-
generation cephalosporins, re-emphasize the importance of
continued surveillance in the treatment of enteric fever
[11]. Indeed, there are sporadic reports of high MICs to
ceftriaxone in typhoidal salmonellae, [9,10] via the presence
of CTX-M-15 and SHV-12 ESBLs. In our opinion, the
spread of ESBLs in S. Typhi isolates is deeply worrying,
greatly limiting available therapeutic options, and leaving
only the carbapenems and tigecycline as possible treatment
options.
Interestingly, according to our study, there was genotypic
diversity, as determined by PFGE studies among the typhoi-
dal salmonellae circulating in our region. They seem to indi-
cate that multiple, independent clones of S. Typhi exist in
different parts of the world.
In order to better manage and prevent the spread of anti-
microbial resistance, both clinicians and governments require
accurate epidemiological information. At the present
moment, this information tends to be lacking, especially in
countries with large populations and unrestricted ‘over the
counter’ prescription policies, such as India. The spread of
ﬂuoroquinolone-resistant S. Typhi necessitates a change
towards ‘evidence-based’ treatment practices for the treat-
ment of typhoid fever, not least in southern India.
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